Vertex Pharmaceuticals News

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

InterMune, Inc. A reported a drop to a loss in the fourth quarter driven by higher costs.A Reported a loss of $44.5 million in the quarter.

Vertex Pharmaceuticals, a Cambridge-based pharmaceutical company, received FDA approval last week for its new cystic fibrosis treatment.

InterMune, Inc. A will unveil its latest earnings on Thursday, February 9, 2012.A The average estimate of analysts is for a loss of 71 cents per share, a wider loss from the year earlier quarter net loss of 39 cents.

The acquisition is expected to complement Akamai's market-leading site acceleration solutions with technology designed to optimize the speed at which a web page is rendered, regardless of end user device.

In a blinded clinical trial, neither the patient nor the clinician should know who is receiving placebo and who the active drug.

"It's a huge milestone," Richard Fitzpatrick, chief operating officer of the Flatley Discovery Lab, said of Vertex Pharmaceuticals' new drug, Kalydeco.

On January 31st the Cystic Fibrosis Foundation announced that the life-saving drug Kalydeco has been approved by the FDA.

The meteoric rise of its hepatitis C drug Incivek is even more impressive considering that it had to compete with Merck 's sold $865 million worth of Lipitor during its first year.

The Deal : Walgreen and BioScrip announced Thursday that they have entered into a definitive agreement under which Walgreens would acquire certain assets of BioScrip's community specialty pharmacies and centralized specialty and mail service pharmacy businesses and BioScrip would receive a total deal value of approximately $225 million.

When a biotechnology company receives approval for a new drug, that is almost always a catalyst for a huge rally in that company's stock price.

Good day, ladies and gentlemen, and welcome to the Vertex Pharmaceuticals Incorporated Fourth Quarter 2011 Financial Results Conference Call.

Intuitive Surgical, Inc. : Collins Stewart confirmed with Intuitive Surgical management that the Japanese Ministry of Health indicated da Vinci prostatectomy is scheduled to be reimbursed beginning in April.

Vertex Pharmaceuticals Incorporated reported its results for the fourth quarter.

Both occurred well before their PDUFA dates, the date the FDA sets as a goal for making a decision about a product, which is a good sign for the entire drug-development industry.

The first drug that treats the root cause of cystic fibrosis won approval Tuesday, offering a life-changing treatment for a handful of patients with the deadly illness and broader hope for thousands more patients with the inherited disease.

Merck & Co., Inc. will unveil its latest earnings on Thursday, February 2, 2012.

Vertex Pharmaceuticals Inc. 's shares jumped over 6% buoyed by news of the US Food and Drug Administration approving its lead pipeline candidate, Kalydeco , for treating patients suffering from cystic fibrosis .

Analysts at Credit Suisse boosted their EPS estimates on shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Wednesday.

I follow quite a lot of companies -- some more closely than others -- so the usefulness of a watchlist to me cannot be overstated.